Press releases

Documents for the extraordinary general meeting will be available no later than September 21, 2026.

Further to the notice convening the extraordinary general meeting to be held on October 5, 2026, the Board of Directors’ complete proposals for resolutions will be available at the Company’s offices and on the Company’s website, www.klaria.com, no later than September 21, 2026.

Klaria and RTHS enter collaboration agreement for the development of early migraine detection and treatment

Klaria AB and Gothenburg-based RTHS have entered a collaboration agreement that aims to exploit RTHS sensor-based blood dynamics measurements to detect migraine prior to symptoms appearing in patients. 

Summons to extraordinary general meeting of Klaria Pharma Holding AB (publ)

The shareholders of Klaria Pharma Holding AB (publ), company registration number 556959–2917, are hereby summoned to the extra general meeting on 5 October 2026 at 10.00 a.m. at law firm Glimstedt’s Stockholm office, Sturegatan 46 in Stockholm.

Klaria Pharma Holding AB (publ) calls an Extraordinary General Meeting to resolve on a Rights Issue of units and an amendment of the Articles of Association

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE USA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Klaria Pharma Holding AB (publ) ("Klaria" or the “Company") has today resolved to convene an Extraordinary General Meeting on 5 October 2026 at which the shareholders are proposed to resolve on a Rights Issue of units comprising newly issued shares and warrants of series TO1 (the “Rights Issue”), as well as amendments to the share capital limits and the number of shares in the Articles of Association. The Rights Issue is intended to strengthen the Company’s financial position and enable continued commercialization and development-related work relating to the migraine product SAF (Sumatripan Alginate Film). The subscription price is proposed to be 2,40 SEK per unit. The Rights Issue comprises a maximum of 61 494 038 units and, if fully subscribed, will provide the Company with approximately SEK 148 million before deduction of issue costs, of which approximately SEK 13 million may be provided through set-off of existing claims against the Company in accordance with the subscription commitments provided. Klaria has received subscription commitments of approximately SEK 40 million. In addition, the Company intends to further secure the Rights Issue—up to approximately 70–75 percent—through top-up and bottom-up guarantees of SEK 33–38 million each.

Correction: Klaria interm report Q2 2026

Klaria interim report Q2 1 April - 30 June 2026

Klaria reschedules quarterly report date

Klaria Pharma Holding (publ) announces that the quarterly report for Q2 2026 will be published on August 31.

Klaria Receives EU Notification of Allowance for Sumatriptan Alginate Film

Klaria has received a Notice of Allowance from the European Patent Office for the second patent in the Sumatriptan Alginate Film (SAF) patent portfolio.  The Notice of Allowance indicates that the second patent and all claims therein are to be granted in their entirety.

Report from the Annual General Meeting of Klaria Pharma Holding AB (publ)

Today, the Annual General Meeting 2026 of Klaria Pharma Holding AB (publ), reg. no. 556959-2917, was held. Below is a summary of the resolutions adopted by the Annual General Meeting (all in accordance with the proposals presented in the summary to the Annual General Meeting, which has been available on the company’s website www.klaria.com).

Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK

Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that Klaria has entered into an agreement for a bridge loan of 25 MSEK from a Swedish finance company. The agreement also includes an option for the Company to borrow an additional 15 MSEK if necessary, which means that the total possible financing framework amounts to 40 MSEK.

Klaria adjusts annual report release date

Summons to the Annual General Meeting of Klaria Pharma Holding AB (publ)

With a change from what has been previously announced, the shareholders of Klaria Pharma Holding AB (publ), corporate registration number 556959–2917, are hereby invited to attend the Annual General Meeting to be held on 26 June 2026 at 10.00 a.m. CEST at Advokatfirman Glimstedt's Stockholm office, Sturegatan 46 in Stockholm.

Klaria postpones interim Q1 report

Klaria postpones publication of the annual report

Klaria Pharma Holding (publ) announces that the 2025 annual report will be published on May 29th.

Notice of the Annual General Meeting of Klaria Pharma Holding AB (publ)

The shareholders of Klaria Pharma Holding AB (publ), org.nr 556959–2917, are hereby invited to attend the Annual General Meeting to be held on 26 May 2026 at 10.00 a.m. CET at Advokatfirman Glimstedt's Stockholm office, Sturegatan 46 in Stockholm.

Annula Genernal Meeting Date Change:  Klaria Pharma Holding (publ)

Correction: Incorrect inclusion of MAR text in earlier release.Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ)

Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting (all in accordance with the proposal presented in the notice convening the extra general meeting, which have been made available on the Company’s website www.klaria.com).